EP Patent

EP2887923B1 — Ophthalmic formulation of polyoxyl lipid or polyoxyl fatty acid and treatment of ocular conditions

Assigned to Sun Pharmaceutical Industries Ltd · Expires 2023-04-05 · 3y expired

What this patent protects

Patent listed against Sandimmune.

Drugs covered by this patent

Sandimmune (cyclosporine) · Novartis AG (originally Sandoz)

Patent Metadata

Patent number: EP2887923B1
Jurisdiction: EP
Classification: —
Expires: 2023-04-05
Drug substance claim: No
Drug product claim: No
Assignee: Sun Pharmaceutical Industries Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.